Background And Aim: The establishment of an international hospital-based register (HBR) for the French African Pediatric Oncology Group (GFAOP) was a necessary step in the group's clinical research program. With help from the Sanofi Espoir Foundation's "My Child Matters" program, the GFAOP resolved to develop an international HBR network to collect quality data on children attending the Pediatric Oncology Units (POUs).

Methods: All children entering POUs from January 2016 to December 2018 were registered using an online questionnaire. Data collection included information on diagnosis, disease stage, demographics, socioeconomic status, and outcome. An intensive training program was developed to improve both data quality and quantity.

Results: Among the 3348 children registered, 3230 had a suspected cancer, 681 were not confirmed. A diagnosis was confirmed on radiological, clinical, or histological examination for 2549 children including Burkitt lymphoma (516: 20%)-the most frequent diagnosis, Wilms' tumor (459: 18%), retinoblastoma (357: 14%), and acute lymphoblastic leukemia (345: 13%). Of these, 2187 children were treated. Early deaths, abandonment, economic difficulties, and lack of equipment were some of the reasons offered to explain the numbers of undiagnosed and untreated children. Vital status is known for 1994 children: 1187 died and 807 were alive, 551 of these with a follow-up > 12 months.

Conclusion: This work has provided reliable data on children attending the POUs, especially clarifying reasons and occasions for care rupture. The data will help to identify material, human resources, and staff training needs, to evaluate progress, and to encourage consideration of pediatric cancer in national cancer plans.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.29464DOI Listing

Publication Analysis

Top Keywords

pediatric oncology
12
french african
8
african pediatric
8
oncology group
8
group gfaop
8
children
8
data children
8
children attending
8
data
5
development international
4

Similar Publications

Purpose Of Review: This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.

Recent Findings: CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern.

View Article and Find Full Text PDF

Bone marrow mesenchymal stromal cells (BM-MSCs) are integral components of the bone marrow microenvironment, playing a crucial role in supporting hematopoiesis. Recent studies have investigated the potential involvement of BM-MSCs in the pathophysiology of acute lymphoblastic leukemia (ALL). However, the exact contribution of BM-MSCs to leukemia progression remains unclear because of conflicting findings and limited characterization.

View Article and Find Full Text PDF

Liver masses are common in children, however primary malignant neoplasms are rare, representing only 1% of all pediatric cancers. Hepatocellular neoplasms are the most common primary liver malignancies and hepatoblastoma (HB) is the most frequently diagnosed. The incidence of HB, which is increasing, is approximately of 2 cases per million in the United States, followed by hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF

CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL).

Radiology

January 2025

From the Department of Radiology, University Hospital Halle, Ernst-Grube-Strasse 40, 06120 Halle (Saale), Germany (D.S., J.S., J.M.B.); Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany (L.K., T.W.G., R.K.); Diagnostic Imaging and Pediatrics, Warren Alpert Medical School, Brown University, Providence, RI (K.M.M.); Department of Pediatric Radiology, Imaging and Radiation Oncology, Core-Rhode Island, Providence, RI (K.M.M.); Department of Oncology, St Jude Children's Research Hospital, Memphis, Tenn (J.E.F.); Department of Pediatric Hematology and Oncology, University Hospital Giessen-Marburg, Giessen, Germany (C.M.K., D.K.); Medical Faculty of the Martin Luther University of Halle-Wittenberg, Halle (Saale) Germany (C.M.K.); Department of Radiology, University of Wisconsin-Madison, Madison, Wis (S.Y.C.); Roswell Park Comprehensive Cancer Center, Buffalo, NY (K.M.K.); Department of Radiation Oncology, Medical Faculty of the Martin-Luther-University, Halle (Saale), Germany (T.P., D.V.); Department of Radiation Oncology, Mayo Clinic-Jacksonville, Jacksonville, Fla (B.S.H.); Department of Radio-Oncology, Medical University Vienna, Vienna, Austria (K.D.); and Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, Mass (S.D.V.).

Staging of pediatric Hodgkin lymphoma is currently based on the Ann Arbor classification, incorporating the Cotswold modifications and the Lugano classification. The Cotswold modifications provide guidelines for the use of CT and MRI. The Lugano classification emphasizes the importance of CT and PET/CT in evaluating both Hodgkin lymphoma and non-Hodgkin lymphoma but focuses on adult patients.

View Article and Find Full Text PDF

Total hepatectomy and liver transplantation has emerged as a game-changing strategy in the treatment of several liver-confined primary or metastatic tumors, opening the new era of transplant oncology. However, the expansion of indications is going to worsen the chronic scarcity of organs, and new strategies are needed to enlarge the donor pool. A possible source of organs could be developing split liver transplantation (SLT) programs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!